Mouwasat Medical Services Company

SASE:4002 Stock Report

Market Cap: ر.س13.9b

Mouwasat Medical Services Valuation

Is 4002 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 4002 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 4002 (SAR69.5) is trading above our estimate of future cash flow value (SAR35.72)

Significantly Below Future Cash Flow Value: 4002 is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4002?

Key metric: As 4002 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4002. This is calculated by dividing 4002's market cap by their current earnings.
What is 4002's PE Ratio?
PE Ratio18.4x
Earningsر.س755.51m
Market Capر.س13.90b

Price to Earnings Ratio vs Peers

How does 4002's PE Ratio compare to its peers?

The above table shows the PE ratio for 4002 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.8x
4004 Dallah Healthcare
21.2x13.93%ر.س11.4b
4017 Dr. Soliman Abdel Kader Fakeeh Hospital
24.4x21.14%ر.س7.3b
4018 Almoosa Health
27.5x22.54%ر.س5.7b
4005 National Medical Care
17.9x10.26%ر.س5.7b
4002 Mouwasat Medical Services
18.4x10.02%ر.س13.9b

Price-To-Earnings vs Peers: 4002 is good value based on its Price-To-Earnings Ratio (18.4x) compared to the peer average (22.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 4002's PE Ratio compare vs other companies in the SA Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4002 18.4xIndustry Avg. 19.0xNo. of Companies4PE01224364860+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4002 is good value based on its Price-To-Earnings Ratio (18.4x) compared to the SA Healthcare industry average (19x).

Price to Earnings Ratio vs Fair Ratio

What is 4002's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4002 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.4x
Fair PE Ratio19.9x

Price-To-Earnings vs Fair Ratio: 4002 is good value based on its Price-To-Earnings Ratio (18.4x) compared to the estimated Fair Price-To-Earnings Ratio (19.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4002 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س69.50
ر.س89.88
+29.33%
12.33%ر.س113.00ر.س75.50n/a11
Mar ’27ر.س62.05
ر.س89.97
+45.00%
12.53%ر.س114.00ر.س75.50n/a11
Feb ’27ر.س68.40
ر.س91.42
+33.65%
11.82%ر.س114.00ر.س76.00n/a10
Jan ’27ر.س67.00
ر.س91.42
+36.45%
11.82%ر.س114.00ر.س76.00n/a10
Dec ’26ر.س69.00
ر.س90.88
+31.71%
10.58%ر.س105.00ر.س77.00n/a12
Nov ’26ر.س76.85
ر.س91.79
+19.44%
11.05%ر.س107.00ر.س77.00n/a12
Oct ’26ر.س74.70
ر.س89.82
+20.23%
10.89%ر.س107.00ر.س77.00n/a13
Sep ’26ر.س72.00
ر.س93.34
+29.64%
14.23%ر.س125.00ر.س75.00n/a14
Aug ’26ر.س76.00
ر.س92.78
+22.08%
14.61%ر.س125.00ر.س75.00n/a14
Jul ’26ر.س75.50
ر.س92.85
+22.98%
14.61%ر.س125.00ر.س75.00n/a14
Jun ’26ر.س72.50
ر.س94.45
+30.28%
14.85%ر.س125.00ر.س75.00n/a13
May ’26ر.س72.30
ر.س97.13
+34.35%
18.01%ر.س132.00ر.س75.00n/a12
Apr ’26ر.س75.00
ر.س104.33
+39.10%
16.63%ر.س134.20ر.س77.00n/a14
Mar ’26ر.س84.60
ر.س117.41
+38.78%
12.83%ر.س145.00ر.س92.30ر.س62.0514
Feb ’26ر.س92.10
ر.س117.34
+27.40%
12.82%ر.س145.00ر.س92.30ر.س68.4014
Jan ’26ر.س85.80
ر.س119.65
+39.45%
11.72%ر.س145.00ر.س92.30ر.س67.0014
Dec ’25ر.س91.00
ر.س123.29
+35.49%
10.51%ر.س145.00ر.س92.30ر.س69.0014
Nov ’25ر.س94.10
ر.س123.72
+31.47%
10.77%ر.س145.00ر.س90.80ر.س76.8512
Oct ’25ر.س100.00
ر.س124.33
+24.33%
10.90%ر.س145.00ر.س90.20ر.س74.7012
Sep ’25ر.س106.20
ر.س125.75
+18.41%
12.22%ر.س152.00ر.س90.20ر.س72.0012
Aug ’25ر.س117.00
ر.س132.52
+13.26%
10.61%ر.س152.00ر.س96.90ر.س76.0011
Jul ’25ر.س120.00
ر.س128.39
+6.99%
12.70%ر.س152.00ر.س96.90ر.س75.5012
Jun ’25ر.س107.00
ر.س127.48
+19.14%
11.92%ر.س146.00ر.س96.90ر.س72.5012
May ’25ر.س134.00
ر.س126.38
-5.68%
12.40%ر.س146.00ر.س96.90ر.س72.3013
Apr ’25ر.س136.80
ر.س120.50
-11.92%
14.73%ر.س146.00ر.س74.40ر.س75.0013
Mar ’25ر.س123.40
ر.س119.31
-3.32%
14.72%ر.س145.00ر.س71.30ر.س84.6012
ر.س89.88
Fair Value
22.7% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/13 11:45
End of Day Share Price 2026/03/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mouwasat Medical Services Company is covered by 23 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ibrahim ElaiwatAljazira Capital Company
Jassim Al-JubranAljazira Capital Company
Rim Ben Salah GharbiAlphaMena